Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Infliximab Treatment for Refractory Kawasaki Disease in Korean Children

  • Song, Min-Seob (Department of Pediatrics, Paik Hospital, College of Medicine, Inje University) ;
  • Lee, Sang-Bum (Department of Pediatrics, College of Medicine, Kyungpook National University) ;
  • Sohn, Se-Jung (Department of Pediatrics, Mokdong Hospital, College of Medicine, Ewha Womans University) ;
  • Oh, Jin-Hee (Department of Pediatrics, St.Vincent's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Kyung-Lim (Department of Pediatrics, Eastwest Neo Medical Center, College of Medicine, Kyung Hee University) ;
  • Han, Ji-Whan (Department of Pediatrics, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Kim, Chul-Ho (Department of Pediatrics, Paik Hospital, College of Medicine, Inje University)
  • Received : 2009.12.28
  • Accepted : 2010.02.09
  • Published : 2010.07.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: This was a multicenter study to evaluate the usefulness of the tumor necrosis factor-alpha (TNF-${\alpha}$) blocker infliximab for treatment of Korean pediatric patients with refractory Kawasaki disease (KD). Subjects and Methods: Data from 16 patients throughout Korea who were diagnosed with refractory KD and received infliximab were collected retrospectively. Results: Complete response to therapy with cessation of fever occurred in 13 of 16 patients. C-reactive protein (CRP) concentrations decreased following infliximab infusion in all 14 patients in whom it was measured before and after treatment. There were no infusion reactions or complications associated with infliximab except in 1 case with acute hepatitis occurring during treatment followed by calculous cholecystitis 4 months later. Fifteen patients had coronary artery (CA) abnormalities before infliximab therapy. Three had transient mild dilatation and 9 had CA aneurysms, with subsequent normalization in 4 patients, persistent mild dilatation in 3, persistent aneurysm in 2, and there were 3 cases (2 with CA aneurysm, 1 with mild CA dilatation) without follow-up echocardiography. Conclusion: The results of this study suggest that infliximab may be useful in the treatment of refractory KD, and it appears that there is no significant further progression of CA lesions developing after infliximab treatment. Multicenter trials with larger numbers of patients and long-term follow-up are necessary to assess the clinical efficacy and safety of infliximab in refractory KD.

Keywords

References

  1. Kawasaki T, Kosaki F, Okawa S, Shigematsu I, Yanagawa H. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1974;54:271-6.
  2. Kato H, Sugimura T, Akagi T, et al. Long-term consequences of Kawasaki disease: a 10- to 21-year follow-up study of 594 patients. Circulation 1996;94:1379-85. https://doi.org/10.1161/01.CIR.94.6.1379
  3. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-7. https://doi.org/10.1056/NEJM198608073150601
  4. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991;324:1633-9. https://doi.org/10.1056/NEJM199106063242305
  5. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. Pediatr Infect Dis J 1998;17:1144-8. https://doi.org/10.1097/00006454-199812000-00009
  6. Durongpisitkul K, Soongswang J, Laohaprasitiporn D, Nana A, Prachuabmoh C, Kangkagate C. Immunoglobulin failure and retreatment in Kawasaki disease. Pediatr Cardiol 2003;24:145-8. https://doi.org/10.1007/s00246-002-0216-2
  7. Lang BA, Yeung RS, Oen KG, et al. Corticosteroid treatment of refractory Kawasaki disease. J Rheumatol 2006;33:803-9.
  8. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005;146:662-7. https://doi.org/10.1016/j.jpeds.2004.12.022
  9. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2004;110:2747-71. https://doi.org/10.1161/01.CIR.0000145143.19711.78
  10. Weiss JE, Eberhard A, Chowdhury D, Gottlieb BS. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004;31: 808-10.
  11. Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan: Ministry of Health and Welfare; 1984.
  12. Sundel RP, Burns JC, Baker A, Beiser AS, Newburger JW. Gamma globulin re-treatment in Kawasaki disease. J Pediatr 1993;123:657-9. https://doi.org/10.1016/S0022-3476(05)80972-2
  13. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004;364:533-44. https://doi.org/10.1016/S0140-6736(04)16814-1
  14. Freeman AF, Shulman ST. Refractory Kawasaki disease. Pediatr Infect Dis J 2004;23:463-4. https://doi.org/10.1097/01.inf.0000125893.66941.e0
  15. Nachiappan J, May M, Hawker RE, Hong P. Resistant Kawasaki disease. J Paediatr Child Health 2004;40:576-8. https://doi.org/10.1111/j.1440-1754.2004.00467.x
  16. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006;113:2606-12. https://doi.org/10.1161/CIRCULATIONAHA.105.592865
  17. Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose gamma-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6. https://doi.org/10.1067/mpd.2000.104815
  18. Muta H, Ishii M, Egami K, et al. Early intravenous gamma-globulin treatment for Kawasaki disease: the nationwide surveys in Japan. J Pediatr 2004;144:496-9. https://doi.org/10.1016/j.jpeds.2003.12.033
  19. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics 1979;63:175-9.
  20. Wright DA, Newburger JW, Baker A, Sumdel RP. Treatment of immune- globulin resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr 1996;128:146-9. https://doi.org/10.1016/S0022-3476(96)70447-X
  21. Miura M, Ohki H, Yoshiba S, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child 2005;90:1096-7. https://doi.org/10.1136/adc.2004.062299
  22. Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child 2008;93:142-6. https://doi.org/10.1136/adc.2007.126144
  23. Lahdenne P, Vahasalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis 2003;62:245-7. https://doi.org/10.1136/ard.62.3.245
  24. Baldassano R, Braegger CP, Escher JC, et al. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am J Gastroenterol 2003;98:833-8. https://doi.org/10.1111/j.1572-0241.2003.07343.x
  25. Hirono K, Kemmotsu Y, Wittkowski H, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res 2009;65:696-701. https://doi.org/10.1203/PDR.0b013e31819ed68d
  26. Hui-Yuen JS, Duong TT, Yeung RS. TNF-alpha is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol 2006;176:6294-301.
  27. Shin JU, Cho HK, Shin MS. Elevated tumor necrosis factor-alpha in stable angina pectoris. Korean Circ J 2000;30:861-6.
  28. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment Pharmacol Ther 2003;17:75-84.
  29. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104. https://doi.org/10.1056/NEJMoa011110
  30. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7. https://doi.org/10.1097/MPG.0b013e31802f6424

Cited by

  1. Recent advances in the treatment of Kawasaki disease vol.74, pp.11, 2011, https://doi.org/10.1016/j.jcma.2011.09.001
  2. Increased Percentages of Tumor Necrosis Factor-α+/Interferon-T+Lymphocytes and Calprotectin+/Tumor Necrosis Factor-A+ Monocytes in Patients with Acute Kawasaki Disease vol.25, pp.1, 2010, https://doi.org/10.1177/039463201202500112
  3. The Clinical Diagnosis and Management of Kawasaki Disease: a Review and Update vol.18, pp.10, 2016, https://doi.org/10.1007/s11908-016-0538-5
  4. Infliximab for Intravenous Immunoglobulin-Resistant Patients with Kawasaki Disease: A Single-Institute Study vol.33, pp.1, 2017, https://doi.org/10.9794/jspccs.33.43
  5. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients vol.37, pp.7, 2010, https://doi.org/10.1007/s10067-017-3952-7
  6. Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis vol.33, pp.1, 2018, https://doi.org/10.1111/jgh.13850
  7. Interleukin-6 is prone to be a candidate biomarker for predicting incomplete and IVIG nonresponsive Kawasaki disease rather than coronary artery aneurysm vol.19, pp.2, 2010, https://doi.org/10.1007/s10238-018-00544-5
  8. A Cost Comparison of Infliximab Versus Intravenous Immunoglobulin for Refractory Kawasaki Disease Treatment vol.11, pp.1, 2010, https://doi.org/10.1542/hpeds.2020-0188
  9. Clinical profile, treatment and outcome of Kawasaki disease: A single‐center experience from a tertiary care referral center of Assam, north‐east India vol.24, pp.3, 2021, https://doi.org/10.1111/1756-185x.14059